HopeStage
Back to all studies
CompletedNCT02232529

Safety and Drug Levels of MIN-101 in Healthy Volunteers

About this titleRead the official source — NCT02232529
Medication studyAges 18–50United KingdomSchizophrenia
The study in practice

Understand this study

Who was this study for?

Listed age limits: 18 years to 50 years.

Listed locations
Ruddington, NottinghamSee all locations and recruitment
Study phase
Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateSeptember 2014
Recruitment status
Completed
Enrollment listed in the registry
32
Sponsor
Minerva Neurosciences
Sponsor type
Unknown or unclear
Study type
Drug
Intervention type
Drug
Study phase
Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
Locations
United Kingdom
Age range
From 18 Years to 50 Years
Official registry ID
NCT02232529
Official title
Show the full official title

A Two-Part Study Designed to Evaluate the Pharmacokinetic Profile of MIN-101 and Its Main Metabolites Following Single and Multiple Dose Modified Release Prototype Formulation Administration in Healthy Cytochrome P450 2D6 Extensive Metabolizer Male and Female Subjects, and to Evaluate the Relationship Between the Pharmacokinetic Profile of MIN-101 and Its Main Metabolites and Cardiovascular Parameters.

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Ruddington, Nottingham

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Minerva Neurosciences.

Did this study involve medication?

Yes. The study involved medication, including MIN-101 and Placebo.

Who was this study for?

Listed age limits: 18 years to 50 years.

Want to explore more studies?

Explore studies